Cannabigerol for Rheumatoid Arthritis

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Raphael Pharma

Must not be taking: Opiates, Cannabis, Cytochrome inhibitors

Disqualifiers: Chronic conditions, Allergies, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

Duration: 8 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether cannabigerol (CBG), a compound in cannabis, can reduce symptoms of rheumatoid arthritis, which causes joint swelling and pain. Participants will take CBG daily for eight weeks to determine if it improves their condition based on lab results and personal feedback. The trial seeks individuals over 25 in the USA with rheumatoid arthritis, at least two swollen joints, a positive anti-CCP blood test, and no cannabis use in the last eight weeks. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research on CBG's potential benefits for rheumatoid arthritis.

Do I need to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications, but you cannot use opiates or cannabis before the study, and you should not use cytochrome P450 or 3A4 inhibitors. It's best to discuss your current medications with the study team.

Is there any evidence suggesting that cannabigerol (CBG) is likely to be safe for humans?

Research has shown that cannabigerol (CBG), a non-psychoactive compound in cannabis, has been studied for its safety and effects on inflammation. In animal studies, CBG reduced inflammation, showing promise for conditions like rheumatoid arthritis. However, specific information about CBG's safety in humans remains limited.

Many compounds like CBG are believed to help with inflammation and pain. These effects are generally well-tolerated, but detailed safety information for CBG in humans is still being collected. As this study is exploratory, researchers are still gathering detailed safety data for humans. Participants can feel reassured that cannabinoids have shown potential with few serious side effects in similar studies. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Unlike the standard treatments for rheumatoid arthritis, which often include NSAIDs, corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), cannabigerol (CBG) offers a novel approach by utilizing a compound derived from cannabis. Researchers are excited about CBG because it targets the endocannabinoid system, which might modulate inflammation differently than traditional drugs. Additionally, CBG is administered in a simple, once-daily dose of a purified oil, potentially offering a more natural alternative with fewer side effects. This could pave the way for new, plant-based therapies in managing rheumatoid arthritis.

What evidence suggests that cannabigerol might be an effective treatment for rheumatoid arthritis?

Research has shown that cannabigerol (CBG), which participants in this trial will receive, might help reduce inflammation in people with rheumatoid arthritis. Studies have found that CBG can decrease the levels of substances in the body that cause inflammation. Participants who took CBG reported feeling better, and their symptoms improved. CBG also lowered the activity of genes that worsen inflammation. These findings suggest that CBG could help manage symptoms of rheumatoid arthritis. ^{2 3 4 6 7}

Are You a Good Fit for This Trial?

This trial is for adults over 25 with active rheumatoid arthritis, evidenced by at least two swollen joints and a positive anti-CCP blood test. Participants must be university graduates, generally healthy without uncontrolled chronic diseases, live in the USA, and agree to follow study rules including avoiding other cannabis products.

Inclusion Criteria

I have completed a university degree.

I am over 25 years old.

I can read and understand the consent form and am willing to sign it.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening

8 weeks

Visits at Baseline, Week 2, Week 4, Week 6, and Week 8

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Cannabigerol (CBG)

Trial Overview The trial is testing the effectiveness of Cannabigerol (CBG) on patients with active rheumatoid arthritis over an 8-week period. It's a single-group study where all participants receive CBG and their responses are measured through lab tests and self-reports.

How Is the Trial Designed?

Group I: CBG Treatment Experimental Treatment 1 Intervention

Participants will receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening for a duration of eight weeks.

Who Is Running the Clinical Trial?

Raphael Pharma

Lead Sponsor

Trials

1

Recruited

10+

Citruslabs

Industry Sponsor

Trials

94

Recruited

5,100+

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9820932/

Anti-Inflammatory Effects of Cannabigerol in Rheumatoid ... Due to its anti-inflammatory properties, CBG might be suited to treat chronic inflammatory diseases such as rheumatoid arthritis (RA) [4]. RA is ...

2. frontiersin.org frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1705962/full

Regulation of inflammatory pathways by cannabigerol in ... Results: Clinical scores showed significant improvement in the CBG vs. PCB on day 29 and in the GC vs. PCB on days 24, 27, and 29. MMP-3 levels ...

3. sciencedirect.com sciencedirect.com/science/article/abs/pii/S0003496724159870

POS1228 CANNABIGEROL IN THE TREATMENT OF ... Conclusion: Generally, we observed better clinical scores and reduced gene expression levels of pro-inflammatory cytokines in the GBG and CG groups in ...

4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11597810/

Cannabigerol (CBG): A Comprehensive Review of Its ... In this study, CBG treatment improved motor function in mice with Huntington's disease and partially normalized the expression of genes linked ...

5. ard.bmj.com ard.bmj.com/content/83/Suppl_1/722.2

POS1228 CANNABIGEROL IN THE TREATMENT OF ... Conclusion: Generally, we observed better clinical scores and reduced gene expression levels of pro-inflammatory cytokines in the GBG and CG groups in ...

6. rmmj.org.il rmmj.org.il/issues/60/1731/manuscript

Cannabis and Rheumatoid Arthritis: A Scoping Review ... One clinical study observed an increase in pro-inflammatory Th17 helper cells after the consumption of CBD oil in patients with RA.

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10619990/

Cannabis and Rheumatoid Arthritis: A Scoping Review ... Cannabinoids possess beneficial properties as potential treatments for rheumatoid diseases due to their anti-inflammatory and analgesic properties.